Financial Performance & Guidance - GeneDx reported preliminary full year 2025 revenue of $427 million, aligning with previous guidance of $425 to $428 million[73] - The company experienced a 54% growth in exome and genome revenue for full year 2025 (58% excluding a 2024 one-time benefit), exceeding previous guidance of 53% to 55%[73] - Exome and genome volume grew by 30.5% in 2025, meeting the minimum guidance of at least 30%[73] - Adjusted gross margin for 2025 was 71%, consistent with the guided range of 70% to 71%[73] - GeneDx anticipates revenue between $540 to $555 million for full year 2026[76] - The company projects a 33% to 35% growth in exome and genome revenue and volume for 2026[76] Market Position & Growth Strategy - GeneDx holds a leading position with 80% of geneticists preferring their services[8] - The company added 30% more tests to Infinity in 2025 than in the prior 24 years combined[13] - Over 30% of pediatric neurologists now order from GeneDx, indicating strong market penetration[39] - The company's dataset includes >2.5M genetic tests, >50% non-European descent, >8M health records, ~1M exomes & genomes, >7M phenotypic datapoints, and >60% have parental data[25] Expansion & Opportunities - GeneDx is expanding into new markets, including prenatal care, with GenomeDx Prenatal[35, 47] - The company sees a large unmet need in NICUs, where up to 60% of patients could benefit from rWGS, but less than 5% receive genetic testing today[44]

Financial Performance - GeneDx grew revenues to $116.7 million, a 52% increase year-over-year[4] - Exome and genome test revenue grew to $98.9 million, a 65% increase year-over-year[4] - The company delivered an adjusted gross margin of 74%, up from 64% in the third quarter of 2024[4] - Adjusted net income was $14.7 million in the third quarter of 2025[4] - Cash, cash equivalents, marketable securities, and restricted cash were $156.1 million as of September 30, 2025[13] Business Highlights - The company's exome and genome volume grew 33% year-over-year[10] - Exome and genome tests accounted for 43% of all tests reported[10] - GeneDx received FDA Breakthrough Device Designation for the GeneDx ExomeDx and GenomeDx[6] Strategic Initiatives and Market Expansion - GeneDx is participating in the NIH's BEACONS Initiative and Florida's Sunshine Genetics Network for genomic newborn screening[6] - The company is strategically investing to accelerate long-term growth drivers, with Q3 2025 adjusted total operating expenses of $71 million[14, 17] - Medicaid programs are expanding access to exome and genome sequencing, with 36 states covering exome or genome testing and 17 states covering rapid genome sequencing[63] Guidance - The company updated its full-year 2025 revenue guidance to $425 to $428 million[18] - The company expects growth in exome and genome revenue of 53% to 55%[18]